TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03472963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of Genvoya® and a single 800 mg dose of Darunavir®
Description: Men will be instructed to take Single dose of Genvoya® and a single 800 mg dose of Darunavir® per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of Genvoya® and a single 800 mg dose of Darunavir®
Description: Men will be instructed to take Single dose of Genvoya® and a single 800 mg dose of Darunavir® per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of Genvoya® and a single 800 mg dose of Darunavir®
Description: Men will be instructed to take Single dose of Genvoya® and a single 800 mg dose of Darunavir® per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of Genvoya® and a single 800 mg dose of Darunavir®
Description: Men will be instructed to take Single dose of Genvoya® and a single 800 mg dose of Darunavir® per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of Genvoya® and a single 800 mg dose of Darunavir®
Description: Men will be instructed to take Single dose of Genvoya® and a single 800 mg dose of Darunavir® per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of Genvoya® and a single 800 mg dose of Darunavir®
Description: Men will be instructed to take Single dose of Genvoya® and a single 800 mg dose of Darunavir® per oral
Study: NCT04182204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle for up to 8 cycles.
Study: NCT03472963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of Genvoya® and a single 800 mg dose of Darunavir®
Description: Men will be instructed to take Single dose of Genvoya® and a single 800 mg dose of Darunavir® per oral
Study: NCT01577355

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Drug
Description: Single 30 mg oral dose containing 100 micro curies of LY2784544
Study: NCT02403141

Intervention type: OTHER
Intervention: Questionnaire

Intervention type: OTHER
Intervention: Questionnaire

Intervention type: OTHER
Intervention: Questionnaire

Intervention type: OTHER
Intervention: Questionnaire
Study: NCT01579149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg),

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single subcutaneous (SC) dose of placebo
Study: NCT00732641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon
Description: Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
Study: NCT02705443

Intervention type: OTHER
Intervention: No Intervention
Description: Standard of Care Only
Study: NCT04182204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycles.
Study: NCT02705443

Intervention type: OTHER
Intervention: No Intervention
Description: Standard of Care Only

Intervention type: OTHER
Intervention: No Intervention
Description: Standard of Care Only
Study: NCT04827615

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ambuja Cement Foundation's Non Communicable Disease Program
Description: Government level: Strengthening linkages with Govt; Ensuring availability \& affordability of NCD diagnostics and treatment; Establishing a follow-up mechanism with patients to ensure continuity of care \& medication compliance~Provider level: Capacity building of frontline workers; Promotion of interface between community \& service provider~Community level: Screening of hypertension \& diabetes for all adults ≥30 years in the village in coordination with Govt under 'population based screening'; Create awareness of modifiable risk factors and lifestyle change among high-risk population; Community mobilization \& active participation in various health marker days; Formation of support groups, women's groups, self help groups, with involvement of people living with NCDs~Individual level: Behavior change communication with messages on NCD risk factors; Nutrition awareness on healthy and unhealthy food practices

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ambuja Cement Foundation's Non Communicable Disease Program
Description: Government level: Strengthening linkages with Govt; Ensuring availability \& affordability of NCD diagnostics and treatment; Establishing a follow-up mechanism with patients to ensure continuity of care \& medication compliance~Provider level: Capacity building of frontline workers; Promotion of interface between community \& service provider~Community level: Screening of hypertension \& diabetes for all adults ≥30 years in the village in coordination with Govt under 'population based screening'; Create awareness of modifiable risk factors and lifestyle change among high-risk population; Community mobilization \& active participation in various health marker days; Formation of support groups, women's groups, self help groups, with involvement of people living with NCDs~Individual level: Behavior change communication with messages on NCD risk factors; Nutrition awareness on healthy and unhealthy food practices
Study: NCT01084330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: 70mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Iriniotecan 350mg/m2
Study: NCT00390429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study: NCT04182204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 100 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycle.
Study: NCT00390429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study: NCT04182204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 100 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 100 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycle.
Study: NCT01424150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liberal fluid therapy
Description: Liberal protocol group is designed to provide approximately 6.0L per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restrictive fluid therapy
Description: Restrictive protocol group is designed to provide less than 2.0 L water and 120 mmol sodium per day.
Study: NCT02779751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Administered orally
Study: NCT02376790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept was administered by subcutaneous injection once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept was administered by subcutaneous injection once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate capsules taken orally once a week. Dosing was initiated at 10 mg weekly and titrated up to a final dose of 20 mg weekly over a 4-week period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate capsules taken orally once a week. Dosing was initiated at 10 mg weekly and titrated up to a final dose of 20 mg weekly over a 4-week period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Etanercept
Description: Placebo to etanercept was administered by subcutaneous injection once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Methotrexate
Description: Placebo to methotrexate capsules taken orally once a week.
Study: NCT03459989

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Samsung H60 Ultrasound
Study: NCT02182336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA
Description: 1. 480 mg BI 201335 NA in the morning, 240 mg BI 201335 NA in the evening of day 10~2. 240 mg BI 201335 NA bid from day 11 to 23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: days 1, 10 and 19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin sodium
Description: days 1, 10 and 19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: days 1, 10 and 19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: days 1, 10 and 19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide
Description: days 1, 10 and 19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam HCl solution
Description: Days 3 and 21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam HCl oral syrup
Description: days 1, 10 and 19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Days 2 and 20
Study: NCT04105712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Change (low in highly processed foods)
Description: For post-dietary change, food is provided for 3 days (participants provide own food and do food journals the other 2 days to confirm adherence). University of Michigan's Nutrition Obesity Research Center (NORC)'s Metabolic Kitchen prepares the food. Low HP food diet is based on prior methods where participants are placed on an isocaloric diet composed of 5% or less of calories from added sugar and 10% or less of overall calories from total sugar. No foods that meet the criteria for a HP food (defined by Kant and colleagues) that corresponds to: sweeteners (sugar, candy, etc); carbonated and non-carbonated beverages (fruit drinks, sweetened / diet beverages, etc.); baked / dairy desserts (cookies, ice cream, etc.); salted snacks (potato chips, etc.) and fast foods (pizza, cheeseburgers, etc.) are included in diet portions. The overall macro nutrient composition of the diet will be approximately 20-25% of kcal from protein, 30-35% of kcal from fat, and 40-50% of kcal from carbohydrates.
Study: NCT02240420

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life Style Counseling (Star-Mama)
Description: Participants enrolled in the Star-Mama intervention group will receive 1. weekly automated phone calls with prevention-focused queries (e.g., diet, exercise, breastfeeding). 2. If a participant generates a value rated out of range, a health coach who receives daily electronic downloads of STAR-Mama responses will call the participant to coach her about the specific health issue. Participants also hear recorded narratives related to their out of range reply encouraging behavior change. 3. Call-backs enable coaches to engage patients in goals setting/action plans and providing information about community resources
Study: NCT03647956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab (trade name Tecentriq) is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
Study: NCT01729663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSF470 vaccine, BCG, Molgramostim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon alpha 2b
Study: NCT02808013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDS-446

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04950660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Tablet
Description: Caffeine is approved by the FDA as a stimulant. A stimulant approved by the United States Food and Drug Administration (FDA) for the treatment to increase mental alertness and in combination with painkiller to treat migraine headaches. It is approved in the form of pill or tablet.
Study: NCT03647956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer.
Study: NCT04950660

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine Tablet
Description: Caffeine is approved by the FDA as a stimulant. A stimulant approved by the United States Food and Drug Administration (FDA) for the treatment to increase mental alertness and in combination with painkiller to treat migraine headaches. It is approved in the form of pill or tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, empty opaque dark blue blank capsule, taken twice daily. This will be an adjuvant to their standard pain control.
Study: NCT02894255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Study: NCT03030183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilucoplan (RA101495)
Description: 0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
Study: NCT04454138

Intervention type: DEVICE
Intervention: XEN-45 gelatin microstent
Description: Placement either in the subconjunctival space or supratenon's area

Intervention type: DEVICE
Intervention: XEN-45 gelatin microstent
Description: Placement either in the subconjunctival space or supratenon's area
Study: NCT01248585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo tablets taken once daily for 5 days
Study: NCT03647956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.
Study: NCT03891316

Intervention type: DIAGNOSTIC_TEST
Intervention: HFIP and Sevoflurane are measured after 3 consecutive days of work.
Description: Concentration of hexafluoroisopropanol and Sevoflurane are measured in urine by gas chromatography

Intervention type: DIAGNOSTIC_TEST
Intervention: HFIP and Sevoflurane are measured after 3 consecutive days of work.
Description: Concentration of hexafluoroisopropanol and Sevoflurane are measured in urine by gas chromatography

Intervention type: DIAGNOSTIC_TEST
Intervention: HFIP and Sevoflurane are measured after 3 consecutive days of work.
Description: Concentration of hexafluoroisopropanol and Sevoflurane are measured in urine by gas chromatography

Intervention type: DIAGNOSTIC_TEST
Intervention: HFIP and Sevoflurane are measured after 3 consecutive days of work.
Description: Concentration of hexafluoroisopropanol and Sevoflurane are measured in urine by gas chromatography
Study: NCT02667522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Child Interaction Therapy (PCIT)
Description: PCIT includes 12-16 sessions across two phases: the first focused on enhancing positive parenting during child-directed interactions, and the second focused on reducing harsh parenting during parent-directed interactions. Parents receive feedback and coaching on their interactions with the child during sessions.
Study: NCT02714608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginsenoside H dripping pills
Description: Experimental: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginsenoside H dripping pills+Placebo
Description: Experimental: Drug: Ginsenoside H dripping pills+Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
Study: NCT01769638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPO1101
Description: A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 50mg), with a 7-day washout period between the formulations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPO1101D
Description: A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 100mg), with a 7-day washout period between the formulations.
Study: NCT00464711

Intervention type: DRUG
Group type: OTHER
Intervention: Escitalopram
Description: Dose determined per clinical discretion. All participants begin on 10mg po qd of escitalopram, and can increase the dose to 30mg po qd over the 12 weeks of the study.
Study: NCT03891316

Intervention type: DIAGNOSTIC_TEST
Intervention: HFIP and Sevoflurane are measured after 3 consecutive days of work.
Description: Concentration of hexafluoroisopropanol and Sevoflurane are measured in urine by gas chromatography

Intervention type: DIAGNOSTIC_TEST
Intervention: HFIP and Sevoflurane are measured after 3 consecutive days of work.
Description: Concentration of hexafluoroisopropanol and Sevoflurane are measured in urine by gas chromatography

Intervention type: DIAGNOSTIC_TEST
Intervention: HFIP and Sevoflurane are measured after 3 consecutive days of work.
Description: Concentration of hexafluoroisopropanol and Sevoflurane are measured in urine by gas chromatography
Study: NCT02752659

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-measured arm circumference, therapist-measured arm-circumference, perometer-measured arm circumference

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-measured arm circumference, therapist-measured arm-circumference, perometer-measured arm circumference
Study: NCT01571466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccination
Description: * Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~  -\~ 1 x 10e8 pfu/ml~* 3 immunisations at week 0, 4 and 16

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 immunisations at week 0, 4 and 16
Study: NCT02827474

Intervention type: OTHER
Intervention: Patient Interview
Description: Patient intervention includes a 30 minute interview prior to their abortion procedure and a follow up phone-interview that will be 10-minutes and held 24-72 hours from the procedure.

Intervention type: OTHER
Intervention: Provider Interview
Description: For physician participants, providers will be interviewed after completion of the patient's visit and this will be 10-15 minutes.
Study: NCT04303377

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab 140 mg every 2 weeks plus Standard of Care, including optimal lipid lowering treatment (high dose of statin ± ezetimibe)
Study: NCT03866967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK105
Description: intravenous (IV) infusion
Study: NCT03488394

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the α-L-iduronidase cDNA, in their final formulation medium.
Description: The drug product target dose is more or equal to 8x10\^6 CD34+ cells/Kg, with a minimum dose of 4x10\^6 CD34+ cells/Kg and a maximum dose of 35x10\^6 CD34+ cells/Kg.~The product will be injected intravenously.
Study: NCT00741546

Intervention type: PROCEDURE
Intervention: Cardiac Surgery
Description: Cardiac Surgery
Study: NCT03898310

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry extract capsules
Description: Participants in the treatment arm will receive cranberry extract capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Participants in the placebo arm will receive placebo capsules.
Study: NCT01448512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PartnerPlus Intervention
Description: The intervention employs a closed, structured, group intervention limited to 10 participants (women or men). Four weekly, 11/2-2 hour sessions are led by a trained gender-congruent counselor and a peer facilitator and emphasize group participation, cognitive-behavioral skill building, sexual negotiation and experimentation with products.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: 4 time matched sessions focused on health education
Study: NCT02241070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindulness-based intervention
Description: A number of mindfulness techniques, including both formal and informal practices with integration in the context of Mind/Body meditation, were explored in order to cultivate moment-by-moment present awareness with non-judgmental acceptance.
Study: NCT01230450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sub-urethral tape (TVT-O)
Description: Tension free vaginal tape vs. single incision sub-urethral tension free vaginal tape

Intervention type: OTHER
Group type: OTHER
Intervention: stand standard mid-urethral sling (TVT-O)